PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
https://pharmacyte.com/pharmacyte-biotech-rebukes-iroquois-commencement-of-consent-solicitation/
PharmaCyte Biotech Reports Interim Results in Malignant Ascites Mouse Model Study
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature live-cell encapsulation technology,
Iroquois Capital Delivers Open Letter To Pharmacyte Biotech Board Of Directors
roquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc. ("PMCB" or the "Company") (NASDAQ:PMCB) with
PharmaCyte Biotech Issues Response To Iroquois Capital Letter And Announces Additional Steps To Increase Shareholder Value
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) (PharmaCyte), a biotechnology company focused on
PharmaCyte Biotech ~5% Shareholder, Iroquois Capital, Sends Open Letter To Co. Board: ‘Expresses Disappointment in the Board’s Failure to Articulate a Plan to Maximize Shareholder Value…’
Expresses Disappointment in the Board's Failure to Articulate a Plan to Maximize Shareholder Value Amid Prolonged Product Development Efforts Despite the Company's Strong Cash Position
Criticizes the
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers
TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 16.8% to $1.32 during Friday's after-market session. The company's market cap stands at $37.0 million.
PharmaCyte Biotech Successfully Completes 24-Month Stability Study Of Its Clinical Trial Product Candidate
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced
PharmaCyte Biotech Announces Results Of Analysis Of Integration Site Of Cytochrome P450 Gene
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced
PharmaCyte Updates Status Of Investigational New Drug Application For Pancreatic Cancer Candidate
PharmaCyte Biotech Inc (NASDAQ: PMCB)
PharmaCyte Biotech Says After Submission Of IND, FDA Requested Additional Studies And Information As Prerequisite Of PharmaCyte’s IND; Co. Says A Number Of Additional Studies And Assays Have Already Been Completed
PharmaCyte Biotech, Inc. (NASDAQ:PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today provided